Published in

Elsevier, Year Book of Cardiology, (2010), p. 397-399

DOI: 10.1016/s0145-4145(09)79737-0

Massachusetts Medical Society, New England Journal of Medicine, 11(361), p. 1045-1057

DOI: 10.1056/nejmoa0904327

Links

Tools

Export citation

Search in Google Scholar

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

Journal article published in 2009 by 陳文鍾, Plato Investigators: Volpe M. Wallentin L,Becker RC,Budaj A,Cannon CP,Emanuelsson H,Held C,Horrow J,Husted S,James S,Katus H,Mahaffey KW,Scirica BM,Skene A,Steg PG,Storey RF,Harrington RA,Freij A,Thorsén M., Lars Wallentin, Investigators Plato, Richard C. Becker, Andrzej Budaj, Mona Thorsen, Christopher P. Cannon, Håkan Emanuelsson, Claes Held ORCID, Jay Horrow, Steen Husted, Stefan James, Anneli Freij, Hugo Katus and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Red circle
Postprint: archiving forbidden
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

BACKGROUND: Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. METHODS: In this multicenter, double-blind, randomized trial, we compared ticagrelor (180- mg loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600 -mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular events in 18,624 patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation. RESULTS: At 12 months, the primary end point--a composite of death from vascular causes, myocardial infarction, or stroke--had occurred in 9.8% of patients receiving ticagrelor as compared with 11.7% of those receiving clopidogrel (hazard ratio, 0.84; 95% confidence interval [CI ], 0.77 to 0. 92; P